Cargando…

Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma

As a common tumor of the urinary system, the morbidity and mortality related to renal carcinoma, are increasing annually. Clear cell renal cell carcinoma (CCRCC) is the most common subtype of renal cell carcinoma, accounting for approximately 75% of the total number of patients with renal cell carci...

Descripción completa

Detalles Bibliográficos
Autores principales:	GE, WENFEI, SONG, SHIYAN, QI, XIAOCHEN, CHEN, FENG, CHE, XIANGYU, SUN, YONGHAO, WANG, JIN, LI, XIAOWEI, LIU, NANA, WANG, QIFEI, WU, GUANGZHEN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tech Science Press 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229311/ https://www.ncbi.nlm.nih.gov/pubmed/37305384 http://dx.doi.org/10.32604/or.2023.027942

Ejemplares similares

Angiogenesis Pathway in Kidney Renal Clear Cell Carcinoma and Its Prognostic Value for Cancer Risk Prediction
por: Che, Xiangyu, et al.
Publicado: (2021)

Potential Application of Pyroptosis in Kidney Renal Clear Cell Carcinoma Immunotherapy and Targeted Therapy
por: Qi, Xiaochen, et al.
Publicado: (2022)

The Uniqueness of Clear Cell Renal Cell Carcinoma: Summary of the Process and Abnormality of Glucose Metabolism and Lipid Metabolism in ccRCC
por: Qi, Xiaochen, et al.
Publicado: (2021)

Using Genomic and Transcriptome Analyses to Identify the Role of the Oxidative Stress Pathway in Renal Clear Cell Carcinoma and Its Potential Therapeutic Significance
por: Che, Xiangyu, et al.
Publicado: (2021)

Genomic and Transcriptome Analysis to Identify the Role of the mTOR Pathway in Kidney Renal Clear Cell Carcinoma and Its Potential Therapeutic Significance
por: Che, Xiangyu, et al.
Publicado: (2021)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

The role and therapeutic significance of the anoikis pathway in renal clear cell carcinoma
por: Wang, Jin, et al.
Publicado: (2022)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Analysis of genomes and transcriptomes of clear cell renal cell carcinomas identifies mutations and gene expression changes in the TGF-beta pathway
por: Che, Xiangyu, et al.
Publicado: (2022)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

A New Survival Model Based on ADAMTSs for Prognostic Prediction in Clear Cell Renal Cell Carcinoma
por: Wu, Guangzhen, et al.
Publicado: (2021)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

Application of Regulatory Cell Death in Cancer: Based on Targeted Therapy and Immunotherapy
por: Qi, Xiaochen, et al.
Publicado: (2022)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
Publicado: (2021)

Interferon β and Anti-PD-1/PD-L1 Checkpoint Blockade Cooperate in NK Cell-Mediated Killing of Nasopharyngeal Carcinoma Cells
por: Makowska, Anna, et al.
Publicado: (2019)

Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
por: Luo, Fan, et al.
Publicado: (2019)

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells
por: Viramontes, Karla M., et al.
Publicado: (2022)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
por: Tu, Megan M., et al.
Publicado: (2019)

Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade
por: Grauers Wiktorin, Hanna, et al.
Publicado: (2018)

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
por: O’Donnell, Jake S., et al.
Publicado: (2016)

Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
por: Ou, Huilin, et al.
Publicado: (2022)

Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor
por: Mutoh, Tomoyuki, et al.
Publicado: (2023)

Development of a Novel Sphingolipid Signaling Pathway-Related Risk Assessment Model to Predict Prognosis in Kidney Renal Clear Cell Carcinoma
por: Sun, Yonghao, et al.
Publicado: (2022)

A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy
por: Su, Xiaofan, et al.
Publicado: (2022)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells
por: Saleh, Reem, et al.
Publicado: (2019)

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
por: Wang, Ziming, et al.
Publicado: (2018)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
por: Ma, Weijie, et al.
Publicado: (2016)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy
por: Bruns, Michael, et al.
Publicado: (2016)

Pan‐cancer analysis revealing DAAM1 as a novel predictive biomarker for PD‐1/PD‐L1 blockade in clear cell renal cell carcinoma
por: Mei, Jie, et al.
Publicado: (2022)

PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
por: Kamada, Takahiro, et al.
Publicado: (2019)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
por: Tobin, Joshua W. D., et al.
Publicado: (2021)

Identification of a Prognostic Risk Signature of Kidney Renal Clear Cell Carcinoma Based on Regulating the Immune Response Pathway Exploration
por: Wu, Guangzhen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mc9m0389kedn1q1a4q36oj32jc